Sign in
Taking people in United KingdomNo phase

Tests an eye-care pathway with virtual specialist review for people with diabetes

Tests whether opticians can check suspected diabetic eye swelling, with remote specialist review.

Key facts

Who runs it
Hywel Dda Health Board
Where
Haverfordwest, United KingdomSee the site
Trial code
Registry title
Is Community Based Monitoring of Diabetic Maculopathy and Pre-proliferative Diabetic Retinopathy Safe?
Status
Recruiting
People taking part
150 people, planned
Started
20 Nov 2024
Planned end
Sept 2025
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Community based optometry with Virtual Review
  • Usual Care
Record updated
2 May 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with diabetes who were sent to the hospital eye service because doctors suspect diabetic maculopathy or pre-proliferative diabetic retinopathy.

Age
18 years and older
Sex
All sexes can join
Disease stage
Suspected diabetic maculopathy or pre-proliferative diabetic retinopathy, referred to the hospital eye service in HDdUHB

Main reasons for not taking part

  • Under 18 years
  • Already diagnosed with diabetic macular oedema
  • Proliferative diabetic retinopathy

The registry criteria, word for word

Show all 4 criteriaShow less

Who can take part

  • People with diabetes referred to the hospital eye services for review of suspected diabetic maculopathy or pre-proliferative diabetic retinopathy in HDdUHB

Who cannot take part

  • <18 years
  • People with diagnosed diabetic macular oedema
  • People with proliferative diabetic retinopathy

Where in United Kingdom

  • Hwyel Dda University Health BoardHaverfordwest, United KingdomContact: Abigail TaylorTaking people

About the trial

What the trial wants to find out

To assess a pathway using opticians based in their practices and a 'virtual' review by a consultant ophthalmologist, based in the hospital to assess suspected diabetic maculopathy. We want to know if this pathway works, is it acceptable to people with diabetes and what the changes might mean in terms of the outcomes for patients and NHS resources and cost?

Read full original descriptionShow less

Screening by Diabetic Eye Service Wales currently involves taking and as-sessing 2-D (dimensional) digital photographs of the back of the eye (reti-na). Leakage from damaged blood vessels can cause swelling within the central part of the retina, known as maculopathy. This swelling cannot be seen on traditional 2-D images.

Diagnosing maculopathy requires a 3-D camera and a technique known as Optical Coherence Tomography (OCT). OCT is not part of routine screening but, is available in the Hospital Eye Service (HES) and many optician prac-tices. If any changes are seen in the macular region of the retina on 2-D images, the patient will require an OCT scan to see if there is any in-creased thickness. Many patients do not have increased thickness and not everyone with diabetic retinopathy has maculopathy.

Currently after screening, patients who have macular changes that suggest possible maculopathy are referred to the HES for OCT imaging. Many of these patients will not have increased thickness and the appointment could have been better used to see a different patient with increased thickness that requires treatment.

The new pathway that will be investigated in this study involves trained opticians in practices that have an OCT camera taking the required 3-D images and carrying out the initial examination. The images and patient record will then be reviewed by an ophthalmologist working virtually, to decide the management plan. If this pathway is safe and acceptable to people with diabetes, it would reduce the pressure on HES clinics. It will also develop new skills for opticians and allow people to be seen closer to their home, reducing the stress that referrals can create and lowering the carbon footprint of the service.

The 2 groups in the trial

  • ControlExisting treatment, for comparison

    Usual care - Hospital eye service based monitoring with ophthalmologist

    Treatment: Usual Care

  • InterventionTreatment being tested

    Community based optometry OCT imaging with virtual review by ophthalmologist

    Treatment: Community based optometry with Virtual Review

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Feasibility of an Alternative Pathway for Hospital Referrals From Diabetic Eye Screening Wales (DESW) for People Suspected With Sight-threatening Diabetic Eye Disease Diabetic Maculopathy (FARSight-DM)
Plain-language title
Tests an eye-care pathway with virtual specialist review for people with diabetesGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
2 May 2025